fever and increase of pro-inflamatory cytokine with bronchoalveolar lavage
Conditions
Interventions
administration of garenoxacin 200mg per oral 1 hour before the bronchoscopy
no administration
Sponsors
Keio University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: adults agree with the enrolement of study who needs bronchoalveolar lavage to diagnose diffuse lung disease
Exclusion criteria
Exclusion criteria: (1) patient who has history of hypersensitivity reaction or adverse event to quinolones (2) patients who can't be performed bronchoscopy because of respirotry disorder (3) patient who has disability of oral administration (4) patient who has history of convulsion or epilepsy or who has regular administration of anti- epileptic medicine (5) patients who has autoimmune disease or immuno-disorders (6) patients who has administration of systemic corticosteroid (7) patients who are administerd antibiotics within 2 weeks (8) pregnanct or possibility of pregnant or breast feeding (9) patients not suitable to administration of garenoxacin considered by attending physician (10) patients who has possibility of negative impact to diagnosis by administration of garenoxacin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pro-inflamatory cytokine(IL-1, IL-2, IL-6, IL-10), procalcitonin | — |
Secondary
| Measure | Time frame |
|---|---|
| fever, leukocytosis, CRP | — |
Countries
Japan
Contacts
Public ContactNaoki Hasegawa
Keio University Hospital Infection control center
Outcome results
None listed